Glucagon like-peptide 1 receptor and the liver
نویسندگان
چکیده
منابع مشابه
Equine glucagon-like peptide-1 receptor physiology
Background Equine metabolic syndrome (EMS) is associated with insulin dysregulation, which often manifests as post-prandial hyperinsulinemia. Circulating concentrations of the incretin hormone, glucagon-like peptide-1 (GLP-1) correlate with an increased insulin response to carbohydrate intake in animals with EMS. However, little is known about the equine GLP-1 receptor (eGLP-1R), or whether GLP...
متن کاملAn overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning
Metabolic syndrome (MetS) is a clustering of several cardiovascular risk factors that include: obesity, dyslipidemia, hypertension and high blood glucose, and often requires multidrug pharmacological interventions. The management of MetS therefore requires high healthcare cost, and can result in poor drug treatment compliance. Hence drug therapies that have pleiotropic beneficial effects may be...
متن کاملGlucagon-like Peptide-1 in Fishes: The Liver and Beyond1
SYNOPSIS. The incretin hormone glucagon-like peptide-1 (GLP-1), coencoded and expressed in the proglucagon gene in intestine and endocrine pancreas of all vertebrates, is an important regulator of insulin secretion in the postprandial state of mammals. Additionally, the hormone acts in concert with insulin to remove glucose from the plasma. In mammalian B cells, lung, intestine and brain, GLP-1...
متن کاملGlucagon-Like Peptide-1
Ma Glucagon-like peptide-1-(7-36) amide (GLP-1) is a human incretin hormone responsible for the release of insulin in response to food. Pre-clinical and human physiological studies have demonstrated cardioprotection from ischemia-reperfusion injury. It can reduce infarct size, ischemic left ventricular dysfunction, and myocardial stunning. GLP-1 receptor agonists have also been shown to reduce ...
متن کاملGlucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary to develop new drugs, one of which is a glucagon-like peptide-1 (GLP-1) based therapy. GLP-1 has been shown to ameliorate diabetes-related condi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Liver International
سال: 2011
ISSN: 1478-3223
DOI: 10.1111/j.1478-3231.2011.02626.x